Protalix BioTherapeutics’ (PLX) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Protalix BioTherapeutics (NYSE:PLX – Free Report) in a report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $10.00 price objective on the stock. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2023 earnings at ($0.03) EPS, FY2023 earnings at $0.16 EPS and […]
More Stories
GoodRx (NASDAQ:GDRX) Price Target Lowered to $6.00 at KeyCorp
GoodRx (NASDAQ:GDRX – Get Free Report) had its price target cut by KeyCorp from $7.00 to $6.00 in a report...
Farmers Trust Co. Increases Holdings in The Hershey Company (NYSE:HSY)
Farmers Trust Co. boosted its position in The Hershey Company (NYSE:HSY – Free Report) by 4.0% in the 4th quarter,...
Cencora, Inc. (NYSE:COR) Shares Sold by Farmers Trust Co.
Farmers Trust Co. cut its stake in shares of Cencora, Inc. (NYSE:COR – Free Report) by 1.9% during the fourth...
Newmont Co. (NYSE:NEM) Shares Sold by Farmers Trust Co.
Farmers Trust Co. lowered its position in shares of Newmont Co. (NYSE:NEM – Free Report) by 32.6% in the fourth...
Farmers Trust Co. Decreases Stock Position in EQT Co. (NYSE:EQT)
Farmers Trust Co. trimmed its stake in shares of EQT Co. (NYSE:EQT – Free Report) by 2.8% in the 4th...
iShares 1-3 Year Treasury Bond ETF (NASDAQ:SHY) Shares Purchased by Farmers Trust Co.
Farmers Trust Co. lifted its stake in shares of iShares 1-3 Year Treasury Bond ETF (NASDAQ:SHY – Free Report) by...